News
FDA OKs First Drug for Primary Membranous Nephropathy
The Brief
- The FDA expanded the label for the B-cell depleter obinutuzumab (Gazyva) to include treatment of primary membranous nephropathy.
- MedPage Today describes this as the first drug approved for primary membranous nephropathy.
- The FDA announced the new indication on a Friday; the source snippet does not give the exact date or the full conditions of use.
Why it matters
It adds an approved drug option for a kidney disease, which matters to science readers following how laboratory and clinical research becomes treatment.
Who’s affected
- physicians treating kidney disease
- patients with primary membranous nephropathy
- #fda
- #nephrology
- #drug approval
- #obinutuzumab
- #membranous nephropathy
(MedPage Today) -- The FDA has once again expanded the label for the B-cell depleter obinutuzumab (Gazyva), this time to include treatment of primary membranous nephropathy. The new indication, announced by the agency on Friday, stipulates use...